STOCK TITAN

RYTM (NASDAQ: RYTM) insider plans sale of 18,406 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A person filing on behalf of RYTM has submitted a Form 144 notice covering a planned sale of 18,406 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of February 5, 2026. The shares have an indicated aggregate market value of $1,987,295.82, compared with 66,736,056 shares of common stock outstanding. These shares were acquired as restricted stock units from the issuer on February 10, 2025. The form also notes a prior Rule 10b5-1 sale for Hunter Smith of 3,247 common shares on February 4, 2026, generating gross proceeds of $344,145.31.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many RYTM shares are planned for sale in this Form 144?

The Form 144 covers a planned sale of 18,406 shares of RYTM common stock. These shares are to be sold through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of February 5, 2026 and an indicated aggregate market value of $1,987,295.82.

What is the aggregate market value of the RYTM shares to be sold?

The planned sale involves RYTM common shares with an aggregate market value of $1,987,295.82. This value is based on the 18,406 shares listed in the Form 144 and reflects the market pricing used when the notice was prepared.

When and how were the RYTM shares in this Form 144 acquired?

The 18,406 RYTM common shares were acquired on February 10, 2025 as restricted stock units from the issuer. The form identifies the issuer as the source and notes the nature of the acquisition transaction as restricted stock units, with the same date for acquisition and payment.

What prior RYTM stock sales are disclosed for the past three months?

The notice reports 10b5-1 sales for Hunter Smith of 3,247 RYTM common shares on February 4, 2026. These sales generated $344,145.31 in gross proceeds and are the only past-three-month transactions shown in the provided table.

On which exchange will the RYTM shares in this Form 144 be sold?

The planned sale of 18,406 RYTM common shares is listed for the NASDAQ exchange. The broker named is Morgan Stanley Smith Barney Executive Financial Services, with the sale structured under Rule 144 as disclosed in the filing tables.

How many RYTM shares are outstanding compared to the Form 144 sale amount?

The form states that 66,736,056 RYTM common shares are outstanding. The planned sale covers 18,406 shares, providing a baseline reference for the size of this potential transaction relative to the total shares outstanding.
Rhythm Pharmaceu

NASDAQ:RYTM

RYTM Rankings

RYTM Latest News

RYTM Latest SEC Filings

RYTM Stock Data

6.93B
63.63M
0.65%
105.06%
7.48%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON